James Davis is a Psychiatry physician. ClinicalTrials.gov lists 11 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
19654 Promise Rd
Noblesville, IN 460609179
Telephone
317-430-7636Registry record last updated 18 Dec 2015.
Clinical trials
- Effectiveness of a Self-management App in Improving the Control of Asthma Among School Adolescents
Sponsor: Makerere University
- Varenicline Light Smoking Pilot
Sponsor: Duke University
- AXS-05 Phase II Trial on Smoking Behavior
Sponsor: James Davis
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Inspire Medical Systems, Inc.Program year20233 payments
- Alkermes, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
32.6%SSRI9.6%Sertraline Hcl35%Trazodone Hcl27%Escitalopram Oxalate26%Fluoxetine Hcl12%Part D<11 patientsN-methyl-D-aspartate Receptor Antagonist5.6%Namzaric40%Memantine Hcl37%Memantine Hcl Er22%Part D<11 patients+ 8 more classes in this area
Cardiovascular
25.9%Statin7.3%Atorvastatin Calcium77%Pravastatin Sodium23%Part D<11 patientsCalcium channel blocker6.5%Amlodipine Besylate100%Part D≥16 patients+ 5 more classes in this area
Blood & clotting
19.2%Factor Xa inhibitor15.2%Eliquis89%Xarelto12%Part D<11 patientsSalt solutions2.1%Sodium Chloride100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”